Related Experiment Videos
Olfactory testing differentiates between progressive supranuclear palsy and idiopathic Parkinson's disease
R L Doty1, L I Golbe, D A McKeown
1Department of Otorhinolaryngology: Head and Neck Surgery, School of Medicine, University of Pennsylvania, Philadelphia.
Neurology
|May 1, 1993
Summary
Patients with progressive supranuclear palsy (PSP) have significantly better olfactory function than those with Parkinson's disease (PD). This difference suggests smell tests can help differentiate between these neurodegenerative conditions.
Area of Science:
- Neurology
- Neuroscience
- Clinical Diagnosis
Background:
- Olfactory dysfunction is a hallmark of idiopathic Parkinson's disease (PD).
- Progressive supranuclear palsy (PSP) shares motor symptoms with PD and is often misdiagnosed.
- Investigating olfactory function in PSP is crucial for differential diagnosis.
Purpose of the Study:
- To determine if olfactory dysfunction is present in progressive supranuclear palsy (PSP).
- To compare olfactory function between PSP patients, Parkinson's disease (PD) patients, and normal controls.
- To assess the utility of olfactory testing in differentiating PSP from PD.
Main Methods:
- Administered the University of Pennsylvania Smell Identification Test to 21 PSP patients.
- Conducted odor detection threshold tests on 17 PSP patients.
- Compared olfactory scores of PSP patients with age, sex, and smoking-matched PD patients and normal controls.
Main Results:
- PSP patients exhibited markedly superior olfactory function compared to PD patients.
- Olfactory function in PSP patients did not significantly differ from normal controls.
- No correlation was found between olfactory scores and motor severity, disease stage, or medication in either PSP or PD groups.
Conclusions:
- Patients with PSP and PD demonstrate significant differences in olfactory abilities.
- Olfactory testing may serve as a valuable tool for the differential diagnosis of PSP and PD.
- Distinct olfactory profiles support the separation of these neurodegenerative diseases.